ArticleScientific reports2017
Field-friendly serological tests for determination of M. leprae-specific antibodies.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Accuracy of rapid point-of-care serological tests for leprosy diagnosis: a systematic review and meta-analysis.Memorias do Instituto Oswaldo Cruz · 2022Pooled it
- Detection of anti-M. leprae antibodies in children in leprosy-endemic areas: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.PLoS neglected tropical diseases · 2017Trial
- Yes/No Quantitative Analysis of Single-Stranded Oligonucleotides with Lateral Flow Assays.Biosensors · 2026Article
- Seroprevalence ofThe Lancet regional health. Southeast Asia · 2026Article
- Implementation of ML Flow for leprosy contacts in Brazil: Opportunities, pitfalls, and safeguards.PLoS neglected tropical diseases · 2026Review
- Decoding leprosy: immune response, clinical manifestations and emerging diagnostic approaches.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Review
- Anti-phenolic glycolipid antibodies inOne health (Amsterdam, Netherlands) · 2025Article
- Large-scale field application of a fingerstick blood test for Mycobacterium leprae infection: Monitoring population-wide effects of case finding and post-exposure prophylaxis on transmission in the Comoros and Madagascar.PLOS global public health · 2025Article
- Sputum host cytokine signatures for diagnosis of TB in children and adults.Frontiers in immunology · 2025Article
- Rapid test for Mycobacterium leprae infection: a practical tool for leprosy.Infectious diseases of poverty · 2024Article
- Leprosy.Nature reviews. Disease primers · 2024Review
- Molecular and Serological Surveillance forAnimals : an open access journal from MDPI · 2024Article
- Target product profiles: leprosy diagnostics.Bulletin of the World Health Organization · 2024Article
- Whole mitogenome sequencing uncovers a relation between mitochondrial heteroplasmy and leprosy severity.Human genomics · 2023Article
- Challenges and advances in serological and molecular tests to aid leprosy diagnosis.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts.BMC infectious diseases · 2023Article
- Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.iScience · 2023Article
- Field-friendly anti-PGL-I serosurvey in children to monitorFrontiers in medicine · 2023Article
- In silico designing of a recombinant multi-epitope antigen for leprosy diagnosis.Journal, genetic engineering & biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of leprosy is key to reduce the ongoing transmission. Antibodies directed against M. leprae PGL-I represent a useful biomarker for detecting multibacillary (MB) patients. Since efficient leprosy diagnosis requires field-friendly test conditions, we evaluated two rapid lateral flow assays (LFA) for detection of Mycobacterium leprae-specific antibodies: the visual immunogold OnSite Leprosy Ab Rapid test [Gold-LFA] and the quantitative, luminescent up-converting phosphor anti-PGL-I test [UCP-LFA]. Test performance was assessed in independent cohorts originating from three endemic areas. In the Philippine cohort comprising patients with high bacillary indices (BI; average:4,9), 94%(n = 161) of MB patients were identified by UCP-LFA and 78%(n = 133) by Gold-LFA. In the Bangladeshi cohort, including mainly MB patients with low BI (average:1), 41%(n = 14) and 44%(n = 15) were detected by UCP-LFA and Gold-LFA, respectively. In the third cohort of schoolchildren from a leprosy hyperendemic region in Brazil, both tests detected 28%(n = 17) seropositivity. Both rapid tests corresponded well with BI(p < 0.0001), with a fairly higher sensitivity obtained with the UCP-LFA assay. However, due to the spectral character of leprosy, additional, cellular biomarkers are required to detect patients with low BIs. Therefore, the UCP-LFA platform, which allows multiplexing with differential biomarkers, offers more cutting-edge potential for diagnosis across the whole leprosy spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.